Besides IO combination, other molecular mechanisms such as epigenetic deregulation can influence innate immune signaling. So we know, for example, that NSD1 mutations are present in 8% of head and neck carcinoma. And patients with these mutations are hypermethylated and immunologically cold with low interferon activity. Also in HPV-positive tumors, NSD2 upregulation driven by E6 oncoproteins similarly yields to immune exclusion...
Besides IO combination, other molecular mechanisms such as epigenetic deregulation can influence innate immune signaling. So we know, for example, that NSD1 mutations are present in 8% of head and neck carcinoma. And patients with these mutations are hypermethylated and immunologically cold with low interferon activity. Also in HPV-positive tumors, NSD2 upregulation driven by E6 oncoproteins similarly yields to immune exclusion. So to restore the type 1 interferon signaling, STING agonists have been explored. In a study led by Fayette and colleagues, the combination of pembrolizumab with STING agonists in PD-L1 positive tumors resulted in responses in 54% of the patients, many of which were durable.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.